CEO, Urovant Sciences
WHY: Leads $285M-valued developer of urology drugs. Unit of Europe-based Roivant, founded by ex-hedge fund manager Vivek Ramaswamy.
RECENT: Irvine firm raised $140M in 2018 IPO, drug designed to treat overactive bladder symptoms still being tested.
NOTABLE: Katkin previously CEO of OC drugmaker Avanir, sold for about $3.5B in 2014. Urovant one of two dozen parent firm spinoffs developing about 40 drugs.
